1. Alollos B.M.: Campylobacter jejuni infections: Update onemerging issues and trends. Clin. Infect. Dis., 2001; 32:1201–1206
2. André F., Van Damme P., Safary A., Banatvala J.: Inactivatedhepatitis A vaccine: Immunogenicity, efficacy, safetyand review of official recommendations for use. Expert Rev.Vaccines, 2002; 1: 9–23
3. Baker K.S., Dallman T.J., Ashton P.M., Day M., Hughes G.,Crook P.D., Gilbart V.L., Zittermann S., Allen V.G., HowdenB.P., Tomita T., Valcanis M., Harris S.R., Connor T.R., SintchenkoV. i wsp.: Intercontinental dissemination of azithromycin-resistant shigellosis through sexual transmission:A cross-sectional study. Lancet Infect. Dis., 2015; 15: 913–921
4. Baker S., The H.C.: Recent insights into Shigella: A majorcontributor to the global diarrhoeal disease burden. Curr.Opin. Infect. Dis., 2018; 31: 449–454
5. Bauman-Popczyk A., Sadkowska-Todys M., Zieliński A.:Choroby zakaźne i pasożytnicze – epidemiologia i profilaktyka.Alfa-Medica Press, Bielsko-Biała, 2014